Sirrus closed $6.5M in Series B financing. The round was co-led by Braemar Energy Ventures and GM Ventures, with participation from existing investors Arsenal Venture Partners and Mitsui Global Investments. The company intends to use the funds to complete process development at pilot scale, design modular facilities and support commercialization of its platform of reactive monomers marketed under the brand names Chemilian™ and Forza™. Sirrus develops monomers and derivatives that allow cycle time reduction, energy savings, and new material selection across automotive, building and construction, electronics, packaging and hygiene. Founded in 2009 and based in Cincinnati, Ohio, the company is led by CEO Jeff Uhrig. It was previously known as Bioformix. Sirrus develops a platform of 1,1‑dicarbonyl substituted alkenes and commercial monomer products (Chemilian™ and Forza™) targeted at adhesives, sealants, coatings, resins and related markets. The technology emphasizes tunable physical properties, fast ambient‑temperature cure speeds, and benefits such as cycle time reduction, energy savings and expanded material choices. Sirrus is pursuing further commercialization of its monomer and polymer technologies and aims to serve announced and soon‑to‑be announced manufacturing partners. To support that commercialization and provide additional working capital, Sirrus secured debt financing in addition to recent equity. In February 2015 the company closed a Series B equity round led by Braemar Energy Ventures and General Motors Ventures, and its total invested capital exceeded $35 million. The company says the new financing provides additional runway to execute its growth plan and advance chemistry‑enabled manufacturing solutions across automotive, building and construction, electronics, packaging and hygiene.

Total raised

$17M

Funding rounds

3

Latest round

Series B

Latest activity

Apr 2015